Platelet Dysfunction Clinical Trial
— STATIPLATOfficial title:
Prospective, Randomized, Single Center, Open Label Study Designed to Evaluate the Effect on Platelet Reactivity in Response to High Doses of Atorvastatin or Rosuvastatin Administered Before Percutaneous Coronary Intervention (PCI)
Verified date | March 2014 |
Source | IRCCS San Raffaele |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: Ethics Committee |
Study type | Interventional |
The purpose of this study is to evaluate the effect of a loading dose of two different statins on platelet reactivity (atorvastatin, metabolized by CYP3A4, and rosuvastatin, which is rather independent of this enzyme)in patients at least 5 days in therapy with aspirin and clopidogrel (with or without an undergoing treatment with statins) undergoing PCI for coronary disease with chronic stable angina and/or evidence of inducible myocardial ischemia.
Status | Completed |
Enrollment | 146 |
Est. completion date | February 2014 |
Est. primary completion date | February 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Age: 18-75 years - Patients with chronic stable angina - Patients with coronary artery disease or with de novo stent restenosis of native vessels. - Patients who are able to understand the significance of this study and to adhere to recruitment by signing the informed consent. Exclusion Criteria: - Acute Coronary Syndromes with an enzymatic movement (STEMI, NSTEMI). - Allergy or intolerance to atorvastatin, rosuvastatin, aspirin, clopidogrel. - Altered basal level of transaminase or CPK. - Patient with history of hepatitis-acute/chronic. - Patients already receiving high-dose statins. - Contraindications to antiplatelet therapy. - Patients with acute inflammatory disease and/or underlying chronic (hepatitis, pneumonia, urinary tract, rectum ulcerative colitis etc.). - Patients with anemia (haemoglobin <8.5 mg/dl), leukocytosis (WBC> 12.000 mm3), leukopenia (WBC <3000 mm3), platelet count <100.000; hypersplenism. - Patients with malignant disease. - Patients enrolled in other studies not yet completed. - Patients with known allergy / intolerance to statins. - Pregnant women and women who are breastfeeding. - Patients with myopathy (muscle pain and unexplained repeated) |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | IRCCS San Raffaele Monte Tabor | Milan |
Lead Sponsor | Collaborator |
---|---|
IRCCS San Raffaele |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area Under the Aggregation Curve (AUC) measured with the Multiplate 5.0 Analyzer | Evaluation of the effect of a loading dose (LD) of two different statins on platelet reactivity (atorvastatin and rosuvastatin) in terms of difference between AUC value before statin LD and after 12 hrs statin LD. The Area Under the Aggregation Curve (AUC) will be measured with the Multiplate 5.0 system. | Evaluation of platelet reactivity (in terms of AUC) two time points. | No |
Secondary | Incidence of periprocedural myocardial infarction | To evaluate if the loading dose of statin prevent the periprocedural myocardial damage measured by CK and CK-MB The measurments will be done once before the procedure and at 6 and 12 hours after. | CK and CK-MB evaluated before the procedure and two time points up to 12 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04554901 -
The Effect of Cocoa on Platelet Function Profiles in Patients
|
N/A | |
Completed |
NCT03621020 -
Clinical Performance Evaluation of T-TAS 01 PL Chip
|
||
Completed |
NCT03667066 -
clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
|
||
Recruiting |
NCT05588011 -
Influence of Oxygenator Selection on Platelet Function and Rotational Thromboelastometry Following Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT01454427 -
Influence of Anesthesia Drugs on Impedance Aggregometry
|
N/A | |
Completed |
NCT03188705 -
CES1 Carriers in the PAPI Study
|
Phase 4 | |
Recruiting |
NCT03583229 -
Coronary Artery Disease After Heart Transplantation
|
N/A | |
Recruiting |
NCT05730114 -
Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
|
||
Completed |
NCT03182946 -
Correcting Platelet Dysfunction After Traumatic Brain Injury
|
||
Completed |
NCT05033236 -
Platelets and Complement Activation in Coronary Artery Bypass Graft Surgery (CABG)
|
||
Recruiting |
NCT04419948 -
Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DM
|
N/A | |
Completed |
NCT04400760 -
The Effect of Dapagliflozin on Platelet Function testinG Profiles in Diabetic PatiEnts.
|
Phase 2/Phase 3 | |
Completed |
NCT03458351 -
RIPC and Platelet Activation on Platelet Activation During Cardiopulmonary Bypass
|
N/A | |
Completed |
NCT02368730 -
Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures
|
N/A | |
Recruiting |
NCT06405516 -
Platelet Function After Cardiac Surgery.
|
N/A | |
Not yet recruiting |
NCT04876573 -
Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
|
Phase 2 | |
Completed |
NCT04734028 -
PTRG-DES Consortium
|
||
Completed |
NCT01382134 -
Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction
|
N/A | |
Completed |
NCT03028064 -
Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding
|
||
Completed |
NCT05237492 -
The Influence of Tramadol on Platelet Function
|
Phase 4 |